Natixis Advisors
PTGX icon

Natixis Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Natixis Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Buy
25,459
+2,821
+12% +$295K ﹤0.01% 1073
2026
Q1 		$2.39M Buy
22,638
+2,143
+10% +$190K ﹤0.01% 1043
2025
Q4 		$1.79M Buy
20,495
+3,640
+22% +$298K ﹤0.01% 1081
2025
Q3 		$1.12M Buy
16,855
+3,413
+25% +$194K ﹤0.01% 1285
2025
Q2 		$743K Buy
+13,442
New +$645K ﹤0.01% 1383

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Natixis Advisors's PTGX Position: Q2 2026 in Review

Natixis Advisors increased its Protagonist Therapeutics (PTGX) stake by 12% in Q2 2026, buying an estimated $295K and bringing the position to 25,459 shares worth $3.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1073.

Natixis Advisors first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Natixis Advisors held 25,459 shares of Protagonist Therapeutics worth $3.12M as of Q2 2026.
  • Natixis Advisors bought 2,821 Protagonist Therapeutics shares in Q2 2026, an estimated $295K.
  • Protagonist Therapeutics made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1073 holding.
  • Natixis Advisors first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.